Novo Nordisk has submitted applications to both US and EU regulators for use of its fast-acting insulin Fiasp in children.Original Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.